Which medications interact with fluconazole?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Fluconazole Drug Interactions

Fluconazole interacts with numerous medications through cytochrome P450 enzyme inhibition (particularly CYP2C9, CYP2C19, and CYP3A4), causing clinically significant increases in plasma concentrations of co-administered drugs and risk of QT prolongation when combined with other QT-prolonging agents. 1, 2

Mechanism of Interactions

Fluconazole is a moderate inhibitor of CYP3A4 and CYP2C9, and a strong inhibitor of CYP2C19 2. Among the azole antifungals, fluconazole is the weakest CYP3A4 inhibitor, but its enzyme-inhibiting effects persist for 4-5 days after discontinuation due to its long half-life 2. The dose-dependent nature of these interactions becomes more pronounced at fluconazole doses ≥200 mg daily 3.

Critical Drug Interactions by Category

Cardiovascular Medications

QT-Prolonging Drugs:

  • Amiodarone: Concomitant use increases QT prolongation risk, requiring extreme caution especially with high-dose fluconazole (800 mg) 2
  • Fluoroquinolones, macrolides (clarithromycin, erythromycin), ondansetron: Combined use significantly increases cardiotoxicity risk including torsade de pointes and sudden cardiac death 1, 4
  • The erythromycin-fluconazole combination should be avoided entirely 2

Calcium Channel Blockers:

  • Nifedipine, isradipine, amlodipine, verapamil, felodipine: Fluconazole increases systemic exposure, requiring frequent monitoring for adverse events 2

Anticoagulants

Warfarin and coumarin-type anticoagulants:

  • Fluconazole inhibits CYP2C9, causing increased prothrombin time and bleeding risk (bruising, epistaxis, GI bleeding, hematuria, melena) 4, 2
  • Careful monitoring of prothrombin time is mandatory; warfarin dose adjustment is typically necessary 2

Immunosuppressants

Calcineurin inhibitors and mTOR inhibitors:

  • Cyclosporine, tacrolimus, sirolimus: Fluconazole commonly elevates serum levels through CYP3A4 inhibition 3, 2
  • Among azoles, fluconazole causes the least CYP3A4 inhibition, but interactions remain clinically significant 3
  • Close therapeutic drug monitoring is essential; antirejection medication doses typically require reduction 3
  • The interaction is dose-dependent and more pronounced at fluconazole doses ≥200 mg daily 3

Chemotherapy Agents

  • Nilotinib (chronic myeloid leukemia): Increased QT prolongation risk 1
  • Panobinostat (myeloma): Drug interaction concerns 1
  • Cyclophosphamide: Combination increases serum bilirubin and creatinine; use with caution 2

Central Nervous System Medications

Benzodiazepines:

  • Midazolam: Fluconazole increases plasma concentrations through CYP3A4 inhibition 2

Antidepressants:

  • Amitriptyline, nortriptyline: Fluconazole enhances effects; measure drug levels at therapy initiation and after 1 week, adjust doses accordingly 2

Anticonvulsants:

  • Carbamazepine: 30% increase in serum carbamazepine levels; risk of toxicity requiring dose adjustment based on concentration monitoring 2
  • Phenytoin: Increased phenytoin levels requiring monitoring 2

Analgesics

Alfentanil: Reduced clearance and prolonged half-life; dosage adjustment may be necessary 2

Urological Medications

Abrocitinib: Significantly increased systemic exposure; avoid concomitant use 2

Celecoxib: 68% increase in Cmax and 134% increase in AUC; consider reducing celecoxib dose by half 2

Other Azole Antifungals

Fluconazole itself can interact when combined with itraconazole, creating contraindicated drug-drug interactions 5

Clinical Management Principles

Key monitoring requirements:

  • Therapeutic drug monitoring is not required for fluconazole due to linear pharmacokinetics, except in renal failure where dose modification is needed 1
  • The extensive list of drug-drug interactions continues to expand 1
  • Consultation with an infectious disease expert is recommended before incorporating azoles into treatment regimens 1

Common pitfalls:

  • Forgetting that enzyme inhibition persists 4-5 days post-discontinuation 2
  • Failing to adjust doses of interacting medications when starting or stopping fluconazole
  • Underestimating the cumulative QT prolongation risk when multiple interacting drugs are prescribed
  • Not accounting for the dose-dependent nature of interactions (≥200 mg daily threshold) 3

Special populations:

  • Transplant recipients require particularly vigilant monitoring due to narrow therapeutic windows of immunosuppressants 3
  • Patients with structural heart disease, electrolyte abnormalities, or advanced cardiac failure are at increased risk for life-threatening arrhythmias 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.